Literature DB >> 17548596

IL-27 synthesis induced by TLR ligation critically depends on IFN regulatory factor 3.

Céline Molle1, Muriel Nguyen, Véronique Flamand, Joelle Renneson, François Trottein, Dominique De Wit, Fabienne Willems, Michel Goldman, Stanislas Goriely.   

Abstract

IL-27 is a heterodimeric cytokine composed of EBV-induced gene 3 and p28. Produced by dendritic cells (DCs) in response to TLR ligands, IL-27 recently emerged as a key regulator of inflammatory responses. In this study, we first demonstrate that Toll/IL-1R-containing adaptor inducing IFN-beta and its associated IFN regulatory factor (IRF) 3 transcription factor are critically involved in IL-27p28 expression in mouse DCs stimulated by TLR ligands. We then show that IL-27 serum levels are dramatically reduced in IRF3(-/-) upon LPS injection, indicating a critical role for IRF3 in TLR4-mediated IL-27 production in vivo. We identified an IRF3-binding site within the IL-27p28 promoter region which is required for IL-27p28 gene activation in reporter gene assays. In human DCs, IL-27p28 mRNA was preferentially induced by Toll/IL-1R-containing adaptor inducing IFN-beta-coupled TLR ligands and following CMV infection. Furthermore, chromatin immunoprecipitation studies demonstrate that IRF3 is recruited to the endogenous p28 promoter in TLR4-stimulated human DCs. We conclude that IRF3 activation is a master switch for IL-27 synthesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17548596     DOI: 10.4049/jimmunol.178.12.7607

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  Coordination between TLR9 signaling in macrophages and CD3 signaling in T cells induces robust expression of IL-30.

Authors:  Denada Dibra; Jeffry J Cutrera; Shulin Li
Journal:  J Immunol       Date:  2012-03-09       Impact factor: 5.422

Review 2.  The response of human dendritic cells to co-ligation of pattern-recognition receptors.

Authors:  Tanja Dzopalic; Ivan Rajkovic; Ana Dragicevic; Miodrag Colic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

3.  Suppression of TNF-α and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27.

Authors:  George D Kalliolias; Rachael A Gordon; Lionel B Ivashkiv
Journal:  J Immunol       Date:  2010-10-22       Impact factor: 5.422

Review 4.  Negative regulation of Th17 responses.

Authors:  J S Stumhofer; J Silver; C A Hunter
Journal:  Semin Immunol       Date:  2008-01-24       Impact factor: 11.130

Review 5.  Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease.

Authors:  Shankar Subramanian Iyer; Gehong Cheng
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

6.  FcγRIIIa Signaling Modulates Endosomal TLR Responses in Human CD4+ T Cells.

Authors:  Anil K Chauhan
Journal:  J Immunol       Date:  2017-05-12       Impact factor: 5.422

7.  Persistent loss of IL-27 responsiveness in CD8+ memory T cells abrogates IL-10 expression in a recall response.

Authors:  Georgia Perona-Wright; Jacob E Kohlmeier; Elizabeth Bassity; Tori C Freitas; Katja Mohrs; Tres Cookenham; Haozhong Situ; Edward J Pearce; David L Woodland; Markus Mohrs
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-22       Impact factor: 11.205

8.  Histone deacetylase sirtuin 1 deacetylates IRF1 protein and programs dendritic cells to control Th17 protein differentiation during autoimmune inflammation.

Authors:  Heeyoung Yang; Sang-Myeong Lee; Beixue Gao; Jinping Zhang; Deyu Fang
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

9.  The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice.

Authors:  Beichu Guo; Elmer Y Chang; Genhong Cheng
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

Review 10.  Interleukin-27: balancing protective and pathological immunity.

Authors:  Christopher A Hunter; Rob Kastelein
Journal:  Immunity       Date:  2012-12-14       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.